Actavis in Chinese pharmaceuticals deal

Actavis, the international generic pharmaceuticals company, has signed an agreement with the Zhejiang Chiral Medicine Chemicals Company in Hangzhou, China.

Actavis will take a 90% share in the Chinese company which specialises in research, development and production of active pharmaceutical ingredients (APIs). The acquisition is part of Actavis’ strategy to gain direct access to low cost API manufacturing.

Actavis has already established an API R&D centre in India with a pipeline of 70 products. This new acquisition, together with Actavis’ API manufacturing site in India, will increase the company’s competitiveness as well as being of strategic importance for Actavis in selling APIs to other pharmaceutical companies.

There are substantial overlaps between Chiral’s and Actavis’ product portfolios which will result in significant cost reduction for a number of pharmaceuticals.

Robert Wessman, CEO and President of Actavis said, “This new facility will enable Actavis to further reduce its manufacturing costs and is an important extension of our activities in China. In addition, this further strengthens our backward integration, increasing our API manufacturing capacity.”

Founded in 2001, the Zhejiang Chiral Medicine Chemicals Company employs around 200 people and sells its products to various pharmaceutical companies outside China.

Actavis is a leading generic pharmaceutical company which specialises in the development, manufacture and sale of generic pharmaceuticals. The company has operations in 40 countries and employs around 11,000 staff.

In addition to building up a strategic position in APIs, Actavis produces generic pharmaceuticals at 21 production sites in 13 countries, with an annual capacity of 24 billion tablets and capsules.

In China, Actavis operates a manufacturing site in Guangdong, which produces tablets, capsules, suspensions, solutions, creams and ointments. After this acquisition Actavis will employ around 500 people in China.

Visit the Actavis corporate website for more information on generic pharmaceuticals.

Contact:
Actavis Group
Hjördis Arnadottir
Director, External Communications
Tel: (+354) 535 2300 / 840 7476
E-mail: harnadottir@actavis.com

Chris Bolwig

Recent Posts

SDG\TBWA Wins Red Dot Award for “Canadian Seafood Treasures” in Brand & Communication Design

October 17, 2025,  Oslo, Norway - Canadian Seafood Treasures, the new international brand created by…

2 weeks ago

UK Students Shift from ‘Write My Essay’ Bots to Human-Edited Support, Reveal Trends at BuyEssay.co.uk

London, UK - 16.10.2026 — As artificial intelligence tools become embedded in university life, a…

3 weeks ago

Cyberseer Recognised as an Authorised Managed Detection & Response Service Partner Powered by Darktrace ActiveAI Security Platform™

London, UK - 16.10.2025 — Cyberseer, one of Darktrace’s earliest Managed Security Service Provider (MSSP) partners…

3 weeks ago

Herring Campaign in Europe for the Danish Pelagic Sector

Reykjavik, Iceland, 07.10.2025 - The Icelandic growth agency Ceedr, in collaboration with TBWA in Copenhagen,…

4 weeks ago

Santa Confirms Who’s on the Nice List – Free Personalised Videos for Children

London, UK – October 3, 2025 — Santa has spoken — and this year, he’s…

4 weeks ago

New Survival Guide for High-Net-Worth Individuals Confronts Wealth and Security Risks

Zürich, Switzerland – October 3, 2025 — In an era where visibility equals vulnerability, a…

4 weeks ago